Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.
ZEPHYR / SCIENCE PHOTO LIBRARY
By Allison DeAngelis
May 4, 2026
Biotech Startups and Venture Capital Reporter
Allison DeAngelis
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
